Soligenix announced that a full clinical summary of its HyBryte (synthetic hypericin) program has been published in the peer‑reviewed journal Expert Opinion on Investigational Drugs. The article, titled “Topical Hypericin: A Promising Photodynamic Therapy for Early‑Stage Cutaneous T‑Cell Lymphoma,” consolidates data from all HyBryte trials, including the successful Phase 3 FLASH study and the ongoing confirmatory FLASH 2 study.
The publication marks a key milestone in HyBryte’s development path. The Phase 3 FLASH study demonstrated robust efficacy and an excellent safety profile, while the confirmatory FLASH 2 study—currently enrolling patients—will provide a larger data set and an interim analysis scheduled for the second quarter of 2026. These results are expected to strengthen regulatory submissions and support the company’s commercialization strategy.
Dr. Brian Poligone, chief medical officer, said, “Topical synthetic hypericin represents a paradigm shift in the skin‑directed management of early‑stage CTCL. Its unique mechanism, excellent safety profile, and robust clinical efficacy position it as a formidable potential new agent in the therapeutic armamentarium.” CEO Christopher J. Schaber added, “We are pleased to have Dr. Poligone and his team review the compelling data generated from the HyBryte™ clinical program, enabling the medical community to evaluate its safety, efficacy and utility in early‑stage CTCL. We look forward to completing patient enrollment in the FLASH 2 Phase 3 study later this year, with an interim analysis expected in 2Q 2026.” Schaber also noted, “We are pleased to have reached this important milestone, confirming the expected safety to date in the confirmatory FLASH 2 study. As patient enrollment continues to track with our initial estimates, we anticipate providing an update, including enrollment progress and the blinded aggregate response rate, before year‑end.”
The peer‑reviewed publication enhances HyBryte’s credibility, reinforcing its safety and efficacy claims in a field where treatment options are limited and safety concerns are paramount. The favorable safety profile—non‑mutagenic mechanism and non‑carcinogenic light source—addresses a key headwind for existing therapies that carry secondary malignancy risks. While the market reaction to the announcement has been muted, analysts have expressed mixed views, reflecting broader valuation concerns and the need for further data from FLASH 2 before a definitive commercial outlook can be established.
The company will continue to monitor enrollment and safety data from FLASH 2, with a full‑study topline expected in the second half of 2026. The publication provides a solid foundation for future regulatory submissions and positions HyBryte as a promising candidate to fill an unmet need in early‑stage CTCL.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.